Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Bright Minds Biosciences Inc (DRUG.CN)

Bright Minds Biosciences Inc (DRUG.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting GlobeNewswire - Tue Nov 25, 3:30PM CST

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective...

DRUG : 80.50 (+11.03%)
DRUG.CN : 106.4900 (+6.49%)
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS) GlobeNewswire - Mon Nov 17, 5:50AM CST

-- Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; distinguished global experts in PWS, will support the Company’s PWS program, which...

DRUG : 80.50 (+11.03%)
DRUG.CN : 106.4900 (+6.49%)
Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH GlobeNewswire - Thu Nov 6, 5:30AM CST

-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with Prader-Willi...

DRUG : 80.50 (+11.03%)
DRUG.CN : 106.4900 (+6.49%)
Bright Minds Biosciences to Present at Upcoming Conferences GlobeNewswire - Thu Oct 30, 5:30PM CDT

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective...

DRUG : 80.50 (+11.03%)
DRUG.CN : 106.4900 (+6.49%)
BRIGHT MINDS BIOSCIENCES ANNOUNCES AT-THE-MARKET OFFERING Newswire.ca - Thu Sep 4, 7:00PM CDT

/CNW/ - Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") announces that it has entered into an equity distribution...

DRUG : 80.50 (+11.03%)
DRUG.CN : 106.4900 (+6.49%)
Bright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model GlobeNewswire - Thu Sep 4, 7:30AM CDT

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG) today announced compelling preclinical results for its investigational compound BMB‑201, in a validated isosorbide...

DRUG : 80.50 (+11.03%)
DRUG.CN : 106.4900 (+6.49%)
Bright Minds Biosciences to Present at Upcoming Conferences GlobeNewswire - Mon Aug 25, 7:00AM CDT

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective...

DRUG : 80.50 (+11.03%)
DRUG.CN : 106.4900 (+6.49%)
Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference GlobeNewswire - Wed May 28, 7:00AM CDT

DRUG : 80.50 (+11.03%)
DRUG.CN : 106.4900 (+6.49%)
Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025 GlobeNewswire - Tue May 20, 7:00AM CDT

DRUG : 80.50 (+11.03%)
DRUG.CN : 106.4900 (+6.49%)
Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101 GlobeNewswire - Tue May 13, 7:30AM CDT

DRUG : 80.50 (+11.03%)
DRUG.CN : 106.4900 (+6.49%)

Barchart Exclusives

As Nike Shakes Up Its C-Suite, Should You Buy, Sell, or Hold NKE Stock? Barchart - Sun Dec 7, 9:00AM CST
Nike’s sweeping C-suite overhaul under its “Win Now” plan signals a bold reset. So, is the stock a buy, sell, or hold? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot